RECRUITINGINTERVENTIONAL

Prediction of Effectiveness of rTMS Application in Alzheimer's Patients

Prediction of Cognitive, Neurotrophic, Anti-Inflammatory, and Antioxidant Effectiveness of rTMS Application in Alzheimer's Patients

About This Trial

Since pharmacological methods are insufficient in the treatment processes of Alzheimer's disease, non-pharmacological methods such as Transcranial Magnetic Stimulation (TMS) have started to be tried as a treatment option as in other neurological and psychiatric diseases. Repeated (rTMS) offers a potential treatment pathway for neurological and psychiatric illnesses. rTMS benefit rate may vary depending on many factors such as the region where it is applied, the progression and the disease degree. The possible effects of TMS on Alzheimer's pathophysiology and modification of disease process (neuroprotective, anti-inflammatory and antioxidant) will also be revealed through blood samples taken from patients before and after treatment. These approaches also constitute the original value of our study.

Who May Be Eligible (Plain English)

Who May Qualify: - Have been diagnosed with clinical Alzheimer's Disease in accordance with the NINCDS-ADRDA diagnostic criteria - \>55 years old - Clinical Dementia Rating Scale (CDR) score in the 1-2 range - Not having any other disease that affects their cognitive functions - Volunteer to participate in the study Who Should NOT Join This Trial: - Participant or relative does not give consent - The patient's inability to participate in the entire study procedure (eg living in another city) - The patient's history of head trauma with alcohol/substance abuse - Presence of severe stroke and other neurological sequelae disease in the participant - Presence of a metal implant on the head or having a pacemaker and contraindications for other TMS applications During the study or 1 month before, having/been receiving/receiving an investigational drug targeting Alzheimer's disease or neuromodulation treatment such as tDCS and TMS, other than standard treatment for AD symptom control such as acetylcholine esterase and memantine, with the potential to affect the study Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Have been diagnosed with clinical Alzheimer's Disease in accordance with the NINCDS-ADRDA diagnostic criteria * \>55 years old * Clinical Dementia Rating Scale (CDR) score in the 1-2 range * Not having any other disease that affects their cognitive functions * Volunteer to participate in the study Exclusion Criteria: * Participant or relative does not give consent * The patient's inability to participate in the entire study procedure (eg living in another city) * The patient's history of head trauma with alcohol/substance abuse * Presence of severe stroke and other neurological sequelae disease in the participant * Presence of a metal implant on the head or having a pacemaker and contraindications for other TMS applications During the study or 1 month before, having/been receiving/receiving an investigational drug targeting Alzheimer's disease or neuromodulation treatment such as tDCS and TMS, other than standard treatment for AD symptom control such as acetylcholine esterase and memantine, with the potential to affect the study

Treatments Being Tested

DEVICE

Repetetive Transcranial Magnetic Stimulation

.Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system. A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group.

Locations (1)

Medipol University Hospital

Istanbul, Turkey (Türkiye)